Hepatitis C children

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C children On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C children

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C children

CDC on Hepatitis C children

Hepatitis C children in the news

Blogs on Hepatitis C children

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C children

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

## Recommendations for Diagnosis and Treatment of HCV-Infected Children: AASLD Practice Guidelines 2009[1][edit | edit source]

“  |

1. The diagnosis and testing of children suspected of being infected with HCV should proceed as for adults (Class I, Level B).

2. Routine testing for anti-HCV at birth of children born to HCV-infected mothers is not recommended because of the high rate of positive antibody due to passive transfer from the mother. Testing for anti-HCV may be performed at 18 months of age or older (Class I, Level B).

3. Testing for HCV RNA may be considered at 1-2 months of age in infants born to HCV-infected mothers if early diagnosis is desired (Class II, Level B).

4. Children aged 2-17 years who are infected with HCV should be considered appropriate candidates for treatment using the same criteria as that used for adults. (Class IIa, Level B).

5. Children should be treated with pegylated interferon alfa-2b, 60 μg/m2 weekly in combination with ribavirin, 15 mg/kg daily for a duration of 48 weeks (Class 1, Level B).

| ”

|
|

## References[edit | edit source]

1. ↑ Swan T, Curry J (2009). "Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users". Hepatology (Baltimore, Md.). 50 (1): 323–4, author reply 324–5. doi:10.1002/hep.23077. PMID 19554546. Retrieved 2012-02-21. Unknown parameter `|month=` ignored (help)

Template:WS Template:WH